Frontier Biopharma Limited
13146422
Some Concerns
- Going concern doubt noted in accounts (-10)
Details
Compliance
Last accounts
31/12/2024
group
Next accounts due
30/09/2026
Confirmation statement
Last: 19/01/2026
Due 02/02/2027
Industry
Officers
director · Since 20/01/2021
COMPANY DIRECTOR
BRITISH · UNITED KINGDOM · Age 41
Also on 2 other boards
director · Since 20/01/2021
COMPANY DIRECTOR
TURKISH · TURKEY · Age 66
Also on 1 other board
director · Since 02/02/2021
DIRECTOR
BRITISH · ENGLAND · Age 60
Also on 13 other boards
Persons with Significant Control
Frontier Pharma Limited
Kemp House, 160 City Road, London, EC1V 2NX
Reg: 10130529 · England · Limited Company
Notified 02/02/2021
Mr Joseph Ensink
Dutch · Guernsey · Age 62
Bordage House, Le Bordage, St Peter Port, GY1 1BU
Notified 25/07/2024
Former PSCs
Mr Kiren Lee Naidoo
Ceased 05/03/2024
Mr Joseph Ensink
Ceased 05/03/2024
CompanyRankvs 333+ SIC 64202 peers49
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Risk deductions
Going concern doubt: -10 pts
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Going Concern Doubt
that the renewal will be successful, or that alternative arrangements can be made such as support from shareholders, and thus believe it is appropriate to prepare the financial statements on a going concern basis. However, due to the inherent uncertainty regarding the renewal of the revolving credit facility, we highlight that a material uncertainty exists that may cast significant d
Key FinancialsYear ending 31/12/2024
Net Worth
£10.9M
Balance sheet strength
Cash
—
Cash in the bank
Net Current Assets
£818k
Working capital
Current Assets
—
Current Liabilities
—
Debtors
£2.6M
Cost of Sales
£13.5M
Admin Expenses
£12.6M
Profit After Tax
-£1.5M
People Costs
Balance Sheet
EstimatesDerived
| Year | Implied Profit |
|---|---|
| 2024 | +£9.1M |
| 2023 | -£12.8M |
| 2022 | +£12.8M |
Derived from filed accounts. Not audited figures.